MannKind at Chardan’s 10th Annual Healthcare Conference: pipeline broadens

On Tuesday, 20 October 2026, MannKind (MNKD) utilized Chardan's 10th Annual Healthcare Conference to present an expanded respiratory pipeline and a projected path to profitability, even as executives conceded that the stock remains under pressure. As of the present day, the company's shares are trading at $3.12, representing a 45.5% decline year-to-date and near the lower end of its 52-week range of $2.23 to $6.51; however, InvestingPro analysis suggests the stock is undervalued at current levels, placing it among opportunities on the Most Undervalued list.

The company outlined its growth plans, which encompass inhaled nintedanib, a ralinepag dry-powder program, Furoscix, and Afrezza. The broader conversation focused on the limitations of existing idiopathic pulmonary fibrosis (IPF) treatments and the demand for more tolerable alternatives. The conference also highlighted the tension in the market: while approved antifibrotic drugs can decelerate lung decline, they do not halt the disease, and side effects continue to deter many patients from adhering to therapy.

MannKind and Vicore Pharma both argued that future IPF drugs will likely require combination treatment rather than replacing every existing option. Both companies are confident in their financial capacity to fund operations and achieve profitability next year without raising additional capital. Vicore Pharma completed a dual listing on U.S. exchanges during the summer, which is expected to broaden its institutional investor base.

The FDA is anticipated to make a decision on nebulized treprostinil for IPF in April, a decision that could influence the subsequent phase of competition in the disease. Dr. Berger, a clinical expert on the panel, emphasized that current antifibrotic drugs slow disease progression but do not stop it and that tolerability restricts the number of patients who can remain on treatment.

The panel further discussed the IPF market's openness to new entrants, despite the presence of more drugs in development. Speakers pointed to various factors reshaping the field, including new oral agents in development, the pending FDA decision on treprostinil, and the growing importance of combination therapy. Dr. Berger noted that the disease remains fatal, with a three- to five-year survival rate, underscoring the high unmet need.

He also suggested that more tolerable therapies may have lower efficacy requirements than drugs with more severe side effects. MannKind's financial foundation is robust enough to support multiple programs simultaneously. The company reported a current ratio of 1.72, revenue growth of 30% over the last twelve months to $393.6 million, and a gross margin of 75%.

InvestingPro Tips predict the company will become profitable this year, with earnings per share forecast at $0.03 for fiscal 2026—a significant improvement from its current loss of $0.16 per share.